#Pradefovir Treatment in Patients with Chronic Hepatitis #B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial

Pradefovir is a liver-targeted prodrug of adefovir, a nucleotide analog with antiviral activity against hepatitis B virus (HBV) DNA polymerase. This phase 2 study compared the efficacy and safety of oral pradefovir (30mg, 45mg, 60mg, and 75mg) versus tenofovir disoproxil fumarate (TDF; 300mg) and aimed to identify the most appropriate dose of pradefovir for the …

Continue reading #Pradefovir Treatment in Patients with Chronic Hepatitis #B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial